中国药业2024,Vol.33Issue(9) :4-7.DOI:10.3969/j.issn.1006-4931.2024.09.002

盐酸吗啡渗透泵片片芯促渗剂研究

Penetration Enhancers of Tablet Core of Morphine Hydrochloride Osmotic Pump Tablets

周成林 张安杰 张太伦 王书兰 毛文星 封海霞
中国药业2024,Vol.33Issue(9) :4-7.DOI:10.3969/j.issn.1006-4931.2024.09.002

盐酸吗啡渗透泵片片芯促渗剂研究

Penetration Enhancers of Tablet Core of Morphine Hydrochloride Osmotic Pump Tablets

周成林 1张安杰 1张太伦 1王书兰 1毛文星 2封海霞2
扫码查看

作者信息

  • 1. 西南药业股份有限公司,重庆 400038
  • 2. 重庆市食品药品检验检测研究院·国家药品监督管理局麻醉精神药品质量监测重点实验室,重庆 401121
  • 折叠

摘要

目的 探讨盐酸吗啡渗透泵片片芯促渗剂的选择.方法 以体外释药行为为指标‚采用单因素考察法对渗透压活性物质、崩解剂、高分子聚合物的种类与用量进行考察,并根据优化结果进行验证试验.结果 盐酸吗啡渗透泵片片芯处方中渗透压活性物质为 60%乳糖,不加崩解剂,不加高分子聚合物,符合该品缓释规律.按处方工艺制备 3 批半透膜包衣片,其释放曲线良好,加速稳定性试验条件下体外累积释放度未发生显著变化.结论 盐酸吗啡渗透泵片片芯促渗剂选择 60%乳糖‚20 h时体外累积释放度达 85%以上,产品质量稳定.

Abstract

Objective To investigate the selection of penetration enhancers for the tablet core of Morphine Hydrochloride Osmotic Pump Tablets.Methods With the drug release behavior in vitro as an index,the single factor test was used to investigate the types and dosages of osmotic pressure active substances,disintegrants,and polymer,and validation tests were conducted according to the optimization results.Results The osmotic pressure active substance in the tablet core prescription of Morphine Hydrochloride Osmotic Pump Tablets was 60%lactose,without the addition of disintegrants or high molecular weight polymers,which met the sustained release law of the product.The release curve of three batches of semi-permeable film-coated tablets prepared according to the prescription process was good,and there was no significant change in the cumulative release in vitro under the accelerated stability test.Conclusion The 20-hour release of Morphine Hydrochloride Osmotic Pump Tablets was more than 85%when 60%lactose was selected as the penetration enhancers for the tablet core of Morphine Hydrochloride Osmotic Pump Tablets,and the quality of the product was stable.

关键词

盐酸吗啡渗透泵片/促渗剂/体外累积释放度

Key words

Morphine Hydrochloride Osmotic Pump Tablets/penetration enhancer/in vitro release

引用本文复制引用

基金项目

重庆市技术创新与应用发展专项资助面上项目(CSTB2022TIAD-GPX0071)

出版年

2024
中国药业
重庆市食品药品监督管理局

中国药业

CSTPCD
影响因子:1.369
ISSN:1006-4931
参考文献量13
段落导航相关论文